Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Sophie Cairns, Senior Analyst, IHS Life Sciences
What does the introduction of Health Technology Assessment (HTA) mean for Japan’s pharmaceutical sector? A discussion of the implications of the growing importance of cost-effectiveness criteria for market access in Japan.